Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?
- PMID: 25030944
- DOI: 10.2174/1574891x09666140717102358
Which patients have greatest need for elvitegravir/cobicistat/ emtricitabine/tenofovirDF-based therapy?
Abstract
Elvitegravir/cobicistat/emtricitabine/tenofovirDF (EVG/COBI/FTC/TDF) is the new single-tablet, fixed-dose formulation containing an integrase strand transfer inhibitor recently approved as antiretroviral treatment. In this paper we analysed its use and advantages in naïve and experienced HIV-infected patients and we focused on special populations in which EVG/COBI/FTC/TDF could be a suitable option. Furthermore the manuscript reports the recent patent of EVG which may have an influence on the management of HIV-infected patients in the next future.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical